Exhibit 99.1






                        PHOENIX INTERNATIONAL RE-ALIGNS
                               GLOBAL OPERATIONS

  -- Company is focused on the integration of its global operations to better
       serve its customers and realize improved operating efficiencies --

Montreal, Quebec - November 29, 1999 - Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research
Organizations (CROs), today announced that it is re-aligning its global
operations to better serve its international customers, improve its operating
efficiencies and meet anticipated future growth in demand for its services.

Under the direction of recently appointed CEO, Ian Lennox, Phoenix International
will now comprise four fully integrated global service units:

 .    Discovery and Preclinical Services, headed by Dr. Nigel Brown;
 .    Global Analytical and Phase I Services, headed by Dr. Stephane Huguet;
 .    Clinical Research,  Americas, headed by Dr. Susan Thornton;
 .    Clinical Research, Europe/Asia, headed by Dr. Lucien Steru.

Phoenix International's new service units will be supported by David Moszkowski,
Finance, Tax, & Treasury, George Engelberg, Information Technology, and a small
corporate services group.

"Our new business structure will enable better allocation of people and capital
as we shift the company from a geographically independent group of business
entities, to a fully integrated, global CRO," said Ian Lennox. "The re-alignment
will offer our customers improved access to our global services."

This new strategic organizational structure is designed to consolidate and
leverage the company's acquisitions to improve its overall operations and
profitability. Customer service will be enhanced through greater flexibility,
improved efficiencies and better allocation of resources.

                                   -- more --


About Phoenix International

Phoenix International is one of the world's leading contract research
organizations. The Company provides a wide spectrum of clinical, analytical,
preclinical, drug discovery support and ancillary services to the pharmaceutical
and biotechnology industries. Since beginning its operations in 1989, Phoenix
International has grown to approximately 2,400 employees worldwide, of whom more
than 215 have either medical degrees or PhD's and over 240 others have masters
level education.  Headquartered in Montreal, Quebec, Phoenix International has
operations throughout Europe and North America and research facilities in
Australia, Israel and South Africa. Phoenix International is on the World Wide
Web at www.pils.com.
       ------------

This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.

FOR MORE INFORMATION, PLEASE CONTACT:

Richard Gareau
Director, Corporate Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033
Fax: (514) 333-8861
E-mail:   gareaur@pils.com